Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001714899-24-000110
Filing Date
2024-04-18
Accepted
2024-04-18 16:03:11
Documents
24
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A dnli-20240418.htm   iXBRL DEF 14A 1101673
6 dnli-20240418_g1.jpg GRAPHIC 26538
7 dnli-20240418_g10.jpg GRAPHIC 205096
8 dnli-20240418_g2.jpg GRAPHIC 12023
9 dnli-20240418_g3.jpg GRAPHIC 16783
10 dnli-20240418_g4.jpg GRAPHIC 15697
11 dnli-20240418_g5.jpg GRAPHIC 19971
12 dnli-20240418_g6.jpg GRAPHIC 44711
13 dnli-20240418_g7.jpg GRAPHIC 121256
14 dnli-20240418_g8.jpg GRAPHIC 108420
15 dnli-20240418_g9.jpg GRAPHIC 472841
  Complete submission text file 0001714899-24-000110.txt   4208493

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20240418.xsd EX-101.SCH 4110
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20240418_def.xml EX-101.DEF 2277
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20240418_lab.xml EX-101.LAB 7795
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20240418_pre.xml EX-101.PRE 4974
27 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20240418_htm.xml XML 153017
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38311 | Film No.: 24854290
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)